Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novan Therapeutics’ Nitricil platform technology has proven to be effective against most of the multi-drug resistant pathogens infecting civilian and military health care providers worldwide.
Subscribe to our email newsletter
Specifically, the nitric oxide-releasing technology was found to be effective against Acinetobacter baumannii, a gram-negative bacterium resistant to nearly all antibiotics, which causes pneumonia, urinary tract infection, and combat- and trauma-related wound infections.
Tripler Army Medical Center Department of Clinical Investigation source major Robert Brodnick said: "Novan’s results show efficacy against the three bugs tested in an infected wound model, including Acinetobacter, as well as Candida and Methicillin-resistant Staphylococcus aureus.
"In our study at Tripler, topical nitric oxide reduced S. aureus colonization more effectively than commercially available wound care products and it was the only treatment to show a significant enhancement of the rate of wound healing compared to standard of care."
Novan president and co-founder Dr. Nathan Stasko said: "Nitricil™ is bactericidal, and not simply bacteriostatic, which means that it kills the bugs instead of just inhibiting growth.
"We believe our nitric oxide approach surmounts resistance and induces broad nitrosative and oxidative stress, which results in efficacy against a diverse array of microorganisms."
Novan’s approach to treat multi-drug resistant infection involves stably storing nitric oxide with its Nitricil technology that can then be applied to mimic the immune response in a site-specific, localized fashion.
Nitric oxide has been well-documented to be effective both in vitroand in vivo against many of the ‘qualifying pathogens’ outlined in the Generating Antibiotic Incentives Now (GAIN) provisions of the Food and Drug Administration Safety and Innovation Act (FDASIA).
The company is set to present the antimicrobial results from two preclinical studies at the 2014 Military Health System Research Symposium (MHSRS), underway in Fort Lauderdale, Florida, US.
Based on the results and additional progress of the preclinical program, the company plans to start clinical development for the treatment of chronic wound infections resulting from multi-drug resistant bacteria in the first half of 2015.